OR WAIT null SECS
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Applied Clinical Trials
A compilation of recently released news briefs that pertain to the clinical trials industry.
TransCelerate BioPharma Inc., the non-profit collaboration made up of 20 biopharmaceutical companies, recently unveiled new initiatives in efforts to expand on the group’s clinical and drug safety portfolio. They include:
Verily, Alphabet’s life sciences unit, has formed strategic alliances with Novartis, Otsuka, Pfizer, and Sanofi to develop digitally innovative, patient-centered clinical research programs using Verily’s Project Baseline’s evidence generation platform and tools. The Baseline platform is designed to engage more patients and clinicians in research, increase the speed and ease of conducting studies, and collect more comprehensive, higher quality data.
Over the coming years, the four drugmakers each plan to launch clinical studies leveraging the platform across therapeutic areas such as cardiovascular disease, oncology, mental health, dermatology, and diabetes.
Gilead Sciences and Goldfinch Bio Inc., a biotechnology company focused on developing precision therapies for patients with kidney diseases, have established a strategic collaboration to discover, develop, and commercialize a pipeline of therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases. Under the multi-year deal, Gilead has exclusive options to license worldwide rights to certain products directed toward targets emerging from Goldfinch’s proprietary Kidney Genome Atlas™. Goldfinch will also apply its biology platform of human induced pluripotent stem cell-derived kidney cells and kidney organoids to validate potential drug targets.
Hackensack Meridian Health, New Jersey’s largest health network, announced that the NIH has awarded Dr. David S. Perlin, the chief scientific officer of the network’s Center for Discovery and Innovation, a $33.3 million grant to develop new antibiotics to overcome deadly bacteria in hospitals that have become resistant to current treatments.
ICON plc has acquired a majority shareholding in MeDiNova Research, a site network with research sites in key markets in Europe and Africa, and has the right to acquire the remaining shares in the company by the third quarter of 2020. Headquartered in Coventry, UK, MeDiNova Research is a network of 33 active clinical research sites in the UK, Spain, South Africa, Poland, and Romania.
-Staff and Wire reports